MeiraGTx Holdings (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive update on its late-stage clinical pipeline.
The fiscal year was defined by significant regulatory tailwinds for its lead programs and the execution of high-value strategic collaborations that have transformed the company’s liquidity profile.
The company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 radiation-induced xerostomia (RIX).
This designation, which follows a previously granted Regenerative Medicine Advanced Therapy (RMAT) status, is supported by three-year efficacy data from earlier clinical studies.
MeiraGTx has aligned with the FDA on the endpoints for its ongoing Phase 2 AQUAx2 study, positioning the trial to serve as a pivotal basis for a Biologics License Application (BLA) in the first half of 2027, with a targeted commercial launch in early 2028.
Financially, MeiraGTx reported 2025 license revenue of $75 million, primarily driven by an upfront payment from Eli Lilly and Company as part of a broad strategic collaboration in ophthalmology.
The company also benefited from a $200 million upfront payment related to the formation of Hologen Neuro AI, a joint venture focused on accelerating the AAV-GAD program for Parkinson’s disease.
Despite these non-dilutive inflows, the company reported a net loss of $114.2 million, or $1.42 per share, an improvement from the $147.8 million loss in the prior year.
The company concluded the fiscal year with $68.2 million in cash and cash equivalents.
Management noted that the combination of current cash, pending milestone payments, and funding from the Hologen joint venture is expected to support operations into the second half of 2027.